首页 | 本学科首页   官方微博 | 高级检索  
   检索      


In Silico Derived Small Molecules Bind the Filovirus VP35 Protein and Inhibit Its Polymerase Cofactor Activity
Authors:Craig S Brown  Michael S Lee  Daisy W Leung  Tianjiao Wang  Wei Xu  Priya Luthra  Manu Anantpadma  Reed S Shabman  Lisa M Melito  Karen S MacMillan  Dominika M Borek  Zbyszek Otwinowski  Parameshwaran Ramanan  Alisha J Stubbs  Dayna S Peterson  Jennifer M Binning  Marco Tonelli  Mark A Olson  Robert A Davey  Joseph M Ready  Christopher F Basler  Gaya K Amarasinghe
Institution:1 Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA;2 Roy J. Carver Department of Biochemistry, Biophysics and Molecular Biology, Iowa State University, Ames, IA 50011, USA;3 Biochemistry Undergraduate Program, Iowa State University, Ames, IA 50011, USA;4 Simulation Sciences Branch, US Army Research Laboratory, Aberdeen, MD 21005, USA;5 Department of Cell Biology and Biochemistry, USAMRIID, 1425 Porter St., Fort Detrick, MD 21702, USA;6 Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA;7 Department of Virology and Immunology, Texas Biomedical Research Institute, San Antonio, TX 78227, USA;8 Department of Biochemistry, UT Southwestern Medical Center at Dallas, Dallas, TX 75390, USA;9 Department of Biophysics, UT Southwestern Medical Center at Dallas, Dallas, TX 75390, USA;10 Center for Structural Genomics of Infectious Diseases (CSGID), Chicago, IL, USA;11 Biochemistry Graduate Program, Iowa State University, Ames, IA 50011, USA;12 National Magnetic Resonance Facility at Madison, University of Wisconsin, Madison, 433 Babcock Drive, Madison, WI 53706, USA
Abstract:The Ebola virus (EBOV) genome only encodes a single viral polypeptide with enzymatic activity, the viral large (L) RNA-dependent RNA polymerase protein. However, currently, there is limited information about the L protein, which has hampered the development of antivirals. Therefore, antifiloviral therapeutic efforts must include additional targets such as protein–protein interfaces. Viral protein 35 (VP35) is multifunctional and plays important roles in viral pathogenesis, including viral mRNA synthesis and replication of the negative-sense RNA viral genome. Previous studies revealed that mutation of key basic residues within the VP35 interferon inhibitory domain (IID) results in significant EBOV attenuation, both in vitro and in vivo. In the current study, we use an experimental pipeline that includes structure-based in silico screening and biochemical and structural characterization, along with medicinal chemistry, to identify and characterize small molecules that target a binding pocket within VP35. NMR mapping experiments and high-resolution x-ray crystal structures show that select small molecules bind to a region of VP35 IID that is important for replication complex formation through interactions with the viral nucleoprotein (NP). We also tested select compounds for their ability to inhibit VP35 IID–NP interactions in vitro as well as VP35 function in a minigenome assay and EBOV replication. These results confirm the ability of compounds identified in this study to inhibit VP35–NP interactions in vitro and to impair viral replication in cell-based assays. These studies provide an initial framework to guide development of antifiloviral compounds against filoviral VP35 proteins.
Keywords:
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号